Form 4: ZyVersa Therapeutics CEO Stephen Glover Granted 136,900 Stock Options

ZyVersa Therapeutics, Inc. CEO Stephen C. Glover was granted 136,900 stock options with an exercise price of $0.59, vesting over three years.

Summary

• Stephen C. Glover, the Chief Executive Officer and a Director of ZyVersa Therapeutics, Inc. (ZVSA), was granted 136,900 stock options.
• The stock options have an exercise price of $0.59 per share.
• The grant date for these options was July 11, 2025.
• The options will vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, contingent upon Mr. Glover's continued service.
• The expiration date for these stock options is July 11, 2035.
• Following this transaction, Stephen C. Glover beneficially owns 136,900 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is a standard compensation practice that aligns management incentives with shareholder value creation, indicating continued commitment and a long-term perspective.

Positives

• The grant of 136,900 stock options to CEO Stephen C. Glover aligns management incentives with shareholder interests, promoting long-term value creation.
• The options have a 10-year expiration period (until July 11, 2035), providing a substantial timeframe for the CEO to realize value, which encourages sustained performance.

Future Outlook

The document indicates a future vesting schedule for the granted stock options, with equal annual installments on the first three anniversaries of the July 11, 2025 grant date, subject to the CEO's continued service.

Industry Context

This Form 4 filing details a routine executive compensation event, specifically the grant of stock options, which is a common practice across various industries, including biotechnology, to incentivize leadership.

Related Party Transactions

• The grant of stock options to Stephen C. Glover, who serves as both the Chief Executive Officer and a Director, constitutes a related party transaction as part of his executive compensation package.

Stakeholder Impact

• Shareholders: Potential for future dilution if the options are exercised, but also potential for increased shareholder value if the options are exercised due to stock price appreciation driven by management performance.

Next Steps

• Continued service of Stephen C. Glover to ensure the vesting of the granted stock options.
• Potential future exercise of the stock options by Stephen C. Glover, subject to vesting and market conditions.

Key Dates

Keywords

ZyVersa Therapeutics, ZVSA, Stephen C. Glover, stock options, executive compensation, Form 4, beneficial ownership, CEO, director, insider transaction